Here’s an important thing for investors in this highflying fintech to remember.
It’s not the company’s COVID-19 vaccine.
This company’s numbers are heading in the right direction and its valuation is very cheap.
The outlet REIT’s business has rebounded quite well, but could still have more improvement ahead.
This is more than just a chipmaker.